|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | |||||||||||||||||||
| Cash | |||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||
| Inventories | |||||||||||||||||||
| Notes receivable | |||||||||||||||||||
| Investor receivable | |||||||||||||||||||
| Related Party | |||||||||||||||||||
| Total investor receivable | |||||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||||
| Total current assets | |||||||||||||||||||
| Prepaid expenses, long-term | |||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||
| Deferred offering costs | |||||||||||||||||||
| Operating right of use asset | |||||||||||||||||||
| Intangible assets, net | |||||||||||||||||||
| Goodwill | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| Current liabilities | |||||||||||||||||||
| Accounts payable | |||||||||||||||||||
| Accrued expenses | |||||||||||||||||||
| Notes payable | |||||||||||||||||||
| Related Party | |||||||||||||||||||
| Total notes payable | |||||||||||||||||||
| Operating lease liability, current | |||||||||||||||||||
| Subscription agreement liability – Related Party | |||||||||||||||||||
| Related Party | |||||||||||||||||||
| Total subscription agreement liability – Related Party | |||||||||||||||||||
| Contingent warrant liabilities | |||||||||||||||||||
| Warrant liabilities | |||||||||||||||||||
| Due to Shareholders | |||||||||||||||||||
| Derivative liabilities | |||||||||||||||||||
| Total current liabilities | |||||||||||||||||||
| Note payable, net of current portion | |||||||||||||||||||
| Subscription agreement liability – related party | |||||||||||||||||||
| Related Party | |||||||||||||||||||
| Total subscription agreement liability – related party | |||||||||||||||||||
| Subscription agreement liability, long-term related party | |||||||||||||||||||
| Related Party | |||||||||||||||||||
| Total subscription agreement liability, long-term related party | |||||||||||||||||||
| Pension benefit obligation | |||||||||||||||||||
| Operating lease liability, net of current portion | |||||||||||||||||||
| Deferred tax liability, net | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Redeemable preferred stock, value | |||||||||||||||||||
| Series B Convertible Redeemable Preferred stock | |||||||||||||||||||
| Series C Redeemable Preferred Stock | |||||||||||||||||||
| Series F Redeemable Preferred Stock | |||||||||||||||||||
| Total redeemable preferred stock, value | |||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||
| Common stock, $0.00001 par value, 250,000,000 shares authorized at September 30, 2026 and December 31, 2025; 5,503,327 and 31,201 shares issued at September 30, 2026 and December 31, 2025, respectively; 5,503,324 and 31,198 shares outstanding at September 30, 2026 and December 31, 2025, respectively | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Treasury stock, at cost; 12,934 shares of common stock at December 31, 2024 and 2023 | |||||||||||||||||||
| Treasury stock, at cost; 3 shares of common stock at September 30, 2026 and December 31, 2025 | |||||||||||||||||||
| Due from shareholders | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||||
| Total Onconetix, Inc. stockholders’ equity (deficit) | |||||||||||||||||||
| Non-controlling interest | |||||||||||||||||||
| Total stockholders’ equity (deficit) | |||||||||||||||||||
| Total liabilities, convertible preferred stock, and stockholders’ equity | |||||||||||||||||||
Loading...